Licaminlimab

Oculis, Zug, Switzerland, June 9, 2026 Oculis announced that the first patient has been randomized in the PREDICT-1 registrational...

October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...